Email

Print

Tweet

Digg!

Del.icio.us

Dallas, TX and New York, NY, October 27, 2010

ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has entered into a pre-licensing feasibility agreement with a leading biopharmaceutical company to develop an oral formulation of an undisclosed prostate cancer compound utilizing its proprietary vitamin B-12-based CobOral™ Drug Delivery Technology.  Access will develop CobOral formulations for testing by the biopharma company. Though the terms of the agreement have not been disclosed, Access indicated that any successful formulation developed will be jointly owned by the Parties and subject to a subsequent full licensing agreement.
Read more »

Email

Print

Tweet

Digg!

Del.icio.us

Furthered Cobalamin-Mediated Formulation Interest Leads to New Patent Filings And CobOral™ Branding

Dallas, TX and New York, NY

ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has submitted additional patent applications, covering its Cobalamin-mediated oral drug delivery technology formulations of many global top-100 injectable drugs, as a result of the growing interest surrounding the company’s proprietary oral delivery technology.  The patents cover oral formulations of leading injectables, like bevacizumab (Avastin®), trastuzumab (Herceptin®), adalimumab (Humira®), etanercept (Enbrel®), insulin glargine (Lantus®), and many others.  In addition, Access rebranded its Cobalamin-mediated oral drug delivery technology as CobOral™ delivery technology.
Read more »

Email

Print

Tweet

Digg!

Del.icio.us

Company Reaches Critical Milestone In North American MuGard Commercialization Process

DALLAS, TX and NEW YORK, NY, October 15, 2010

Access Pharmaceuticals, Inc. (OTC BB: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, announced today it has received initial prescriptions for its lead product, MuGard – an FDA-approved, ready-to-use mucoadhesive oral wound rinse for the management of oral mucositis, a debilitating side effect of radiotherapy and/or chemotherapy.  In addition, the Company has received reimbursement for the prescriptions from leading health care providers. Through its consultants and specialty distribution partner, Access’ outreach to payor networks for MuGard prescription reimbursement is ongoing.
Read more »

Email

Print

Tweet

Digg!

Del.icio.us

Patients Experienced 52% Reduction in Pain and Oral Discomfort; MuGard’s Ready-to-Use Formulation Well Accepted By 86% of Patients

DALLAS, TX and NEW YORK, NY, October 11, 2010

Access Pharmaceuticals, Inc. (OTC BB: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, announced the highlights from a poster presentation on European clinical experience of MuGard at this year’s European Society of Medical Oncology Conference in Milan, Italy.   Some of the findings reported in the ESMO presentation included:

• MuGard provided a significant improvement and/or stabilization of oral mucositis lesions and symptoms of oral mucositis (OM) in more than 75% of cancer patients treated with radiotherapy/chemotherapy;

• Patients reported a 52% significant reduction in oral discomfort (oral pain and swallowing ability) in patients with pre-existing lesions of OM, and reported a substantial reduction in the use of pain medication;

• MuGard has a ready-to-use formulation that is well accepted by 86% of patients, as reported in this assessment program;

• No MuGard-related adverse reactions have been identified in clinical practice;

• MuGard represents a valuable therapeutic option in the treatment and prevention of OM in cancer patients undergoing radio/chemotherapy.
Read more »